Table 1. MGMT activity (fmol μg−1 DNA) in extracts of PBMC samples from patients in the treatment groups indicated and as described in the Patients and Methods section.
| Sampling time | LM/TMZ, 40 mg/day | LM/TMZ, 60–80 mg/day | TMZ alone | LM/TMZ on progression | Protracted LM/TMZ |
|---|---|---|---|---|---|
| Pre-treatment | |||||
| N | 28 | 7 | 30 | 9 | 7 |
| Mean | 16.5 | 12.6 | 16.9 | 9.9 | 13.9 |
| Range | 2.30–48.3 | 7.40–18.3 | 4.7–51.6 | 3.7–15.7 | 7–15.5 |
| 2 h | |||||
| N | 3 | — | — | 4 | — |
| Mean | 6.43 | — | — | 1.10 | — |
| Range | 0–15.7 | — | — | 0–4.4 | — |
| 4 h | |||||
| N | 2 | — | — | 3 | 6 |
| Mean | 0 | — | — | 0 | 0.6 |
| Range | — | — | — | 0–3.6 | |
| 6 h | |||||
| N | 27 | 6 | 27 | 7 | — |
| Mean | 0 | 0 | 14.4 | 0 | — |
| Range | — | — | 2.10–51.1 | — | — |
| 8 h | |||||
| N | 2 | — | — | 3 | — |
| Mean | 0 | — | — | 0 | — |
| Range | — | — | — | — | — |
| 24 h | |||||
| N | 26 | 3 | 26 | 4 | — |
| Mean | 0 | 0 | 12.5 | 0 | — |
| Range | — | — | 2.00–30.9 | — | — |
| End of treatment | |||||
| N | — | — | — | — | 4 |
| Mean | — | — | — | — | 0 |
Abbreviations: LM=lomeguatrib; TMZ=temozolomide.